Role of molecular hydrogen in obesity treatment: modulation of GLP-1, irisin, and PGC-1α for improved metabolism.
Nikola Todorović, Jovan Kuzmanović, Dejan Javorac, Sergej M. Ostojic · Medical Gas Research · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
Molecular hydrogen produced a favorable primary result in this randomized human study, supporting further research into its potential for obesity.
Hydrogen water obesity study 2025: what the findings mean
This H2HUBB page translates the technical study record into consumer-friendly language while preserving the scientific details. The increasing prevalence of obesity and non-communicable diseases has become a major global health concern, contributing to significant morbidity and mortality rates. These conditions not only burden healthcare systems but also affect the individual’s quality of life worldwide. As these challenges continue to grow, there is a pressing need to explore treatment options that are effective, affordable, and widely accessible.
Publication: Nikola Todorović, Jovan Kuzmanović, Dejan Javorac, Sergej M. Ostojic, Medical Gas Research, 2025.
What the researchers studied
While traditional pharmaceutical interventions have shown benefits, they often come with limitations, including side effects and/or high costs, highlighting the importance of investigating alternative…
What effects did molecular hydrogen have?
Observed hydrogen effects: The increasing prevalence of obesity and non-communicable diseases has become a major global health concern, contributing to significant morbidity and mortality rates. Dihydrogen is a medical gas with extensively documented antioxidant, anti-inflammatory, and signaling properties, validated in over 1000 studies across more than 100 disease models,1 and has shown significant efficacy in improving clinical endpoints and surrogate markers from metabolic diseases to chronic systemic inflammatory disorders.2 For example, a 6-month randomized clinical trial involving 1088 patients with type 2 diabetes mellitus (T2DM) receiving standard anti-diabetic…
Why these findings matter
The reported benefit supports the therapeutic potential of hydrogen water for obesity under the conditions tested. Because people were studied, this is directly relevant to clinical research, but larger independent trials are still needed before hydrogen can be considered an established treatment.
How strong is this evidence?
This is direct human evidence from a randomized trial, which is generally more informative about treatment effects than an uncontrolled report. The reported sample size was 1088. Randomization: Yes.
Technical study details
- Publication type: Randomized controlled trial
- Evidence type: Human clinical evidence
- Research model or population: Human participants with t2dm
- Sample size: 1088
- Randomized: Yes
- Hydrogen method: Hydrogen water
Limitations and safety
Important limitations: Review conclusions depend on the quality, consistency, and heterogeneity of the included studies.
Safety information: The abstract did not provide detailed safety or adverse-event information.
Original study and H2HUBB research context
This page explains a published research record and does not turn one study into a medical recommendation. Read the original scientific source for the complete methods, statistics, and author conclusions. Compare this result with related evidence in the H2HUBB Molecular Hydrogen Research Library.